Testing two drugs for active Takayasu's arteritis
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This study tests two new medications, vunakizumab and ivarmacitinib, for people with active Takayasu's arteritis (TAK) that is not fully controlled by standard treatments. The goal is to see if these drugs are safe and effective for reducing disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have Takayasu's arteritis that is newly diagnosed or has come back after treatment.
- Your disease must be active despite using steroids and another immune-suppressing drug (not including JAK inhibitors or IL-17 inhibitors).
- You must have at least two signs of active disease, such as symptoms, new findings on imaging, or elevated inflammation markers (ESR or CRP).
- You cannot have severe organ damage from TAK that requires urgent surgery or procedures.
- You cannot have active hepatitis B or C, active tuberculosis, a history of cancer in the last 5 years, poorly controlled diabetes, or a history of blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called deucravacitinib for people with active Takayasu's arteritis (a rare blood vessel disease). It aims to see if the drug can help control inflammation when other treatments have not worked well enough.
This study tests whether ultrasound can track inflammation in blood vessels for people with Takayasu arteritis (a rare condition causing vessel inflammation). You'll have regular ultrasounds to see if this method helps doctors spot disease activity early.
This study collects medical information from patients diagnosed with Takayasu arteritis, a rare disease affecting large blood vessels. By joining, you help researchers better understand this condition and improve care for future patients.
This UK-based study uses a questionnaire to learn about how people with Takayasu arteritis (a rare type of vasculitis) are treated and what they think about their care. If you have TAK, your answers can help doctors understand how to better manage this condition.
This study collects information and blood samples (biomarkers) to better understand Takayasu arteritis and how active it is. It may help researchers find tests that support diagnosis and track disease activity.
This study looks at people with Takayasu's arteritis that also affects the lungs' blood vessels. Researchers want to understand the disease's behavior and outcomes over time.
Hear when a new Takayasu Arteritis (TAK) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.